Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIRTIVITY: Verducatib in Bronchiectasis
NCT06872892Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 46
01
Overview
Phase 3, randomised, double-blind trial of verducatib in bronchiectasis (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Annualised rate of adjudicated pulmonary exacerbations at 76 weeks. Started Jun 2025; status: recruiting.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT06872892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06872892.